Zika Virus VLP (Virus-like Particle) Antigens for Vaccine Candidate and Diagnostic Development

Zika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at a heightened risk of developing Guillain-Barre syndrome and other neurological disorders. In response to the 2015-2016 Zika outbreak, CDC scientists developed a recombinant vaccine candidate as well as reagents and methods to detect ZIKV infection. The recombinant vaccine candidate utilizes adenovirus vector expressed viral envelope proteins. This vector-based vaccine candidate is an efficient platform that elicits a strong response in mouse models; added vaccine testing in rabbit models is underway. Virus-like particles generated from the vector are also being used for ZIKV diagnostics. The US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for CDC's Zika IgM antibody capture enzyme-linked immunosorbent assay (Zika MAC-ELISA) that utilizes VLP technology for in vitro qualitative detection of human IgM antibodies to Zika virus in serum. It can also be used to test cerebrospinal fluid (CSF) when submitted with a patient-matched serum sample. The CDC Zika MAC-ELISA assay is currently in use at qualified laboratories designated by CDC.

Potential Commercial Applications: Competitive Advantages:
  • Development of a Zika virus vaccine
  • Zika VLPs can be used for immunoassay diagnostic development
  • VLP strategy has proven to be very effective inCDC's West Nile virus (WNV) and dengue vaccine development
  • Vaccine research in mouse and rabbit models underway
  • FDA issued an EUA for CDC's Zika MAC-ELISA assay with VLP technology as a component of the assay; the assay is currently in use

Related Invention(s):


Gwong-Jen Chang (CDC)  ➽ more inventions...

Brent Davis (CDC)  ➽ more inventions...

Intellectual Property:
US Pat: - issued -
PCT Application No. PCT/US17/036762 filed on 2017-06-09
US Application No. 16/309,288 filed on 2018-12-12
US Application No. 17/168,889 filed on 2021-02-05

Zika MAC-ELISA Fact Sheet for Health Care Providers [PDF]
Medical Device Safety - Emergency Situations [Webpage]

Collaboration Opportunity:

The Centers for Disease Control and Prevention Technology Transfer Office (TTO) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Zika Virus VLP for Vaccine & Diagnostic Development. For collaboration opportunities, please contact CDC TTO at tto@cdc.gov or 404-639-1330.

Licensing Contact:
Jeremiah Mitzelfelt,
Email: jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

OTT Reference No: E-107-2016-0
Updated: Mar 9, 2020